^
No biomarker
Thyroid Gland Papillary Carcinoma
sorafenib
Sensitive: A1 - Approval
No biomarker
Thyroid Gland Papillary Carcinoma
lenvatinib
Sensitive: A1 - Approval
NTRK2 fusion
Thyroid Gland Papillary Carcinoma
larotrectinib
Sensitive: A2 - Guideline
No biomarker
Thyroid Gland Papillary Carcinoma
denosumab
Sensitive: A2 - Guideline
RET fusion
Thyroid Gland Papillary Carcinoma
selpercatinib
Sensitive: A2 - Guideline
NTRK3 fusion
Thyroid Gland Papillary Carcinoma
entrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Thyroid Gland Papillary Carcinoma
entrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
Thyroid Gland Papillary Carcinoma
entrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Thyroid Gland Papillary Carcinoma
larotrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
Thyroid Gland Papillary Carcinoma
larotrectinib
Sensitive: A2 - Guideline
TMB-H
Thyroid Gland Papillary Carcinoma
pembrolizumab
Sensitive: A2 - Guideline
RET fusion
Thyroid Gland Papillary Carcinoma
pralsetinib
Sensitive: A2 - Guideline
BRAF V600E
Thyroid Gland Papillary Carcinoma
trametinib + dabrafenib
Sensitive: C1 - Off-label
BRAF V600E
Thyroid Gland Papillary Carcinoma
vemurafenib
Sensitive: C1 - Off-label
BRAF mutation
Thyroid Gland Papillary Carcinoma
trametinib + dabrafenib
Sensitive: C2 – Inclusion Criteria
BRAF mutation
Thyroid Gland Papillary Carcinoma
vemurafenib
Sensitive: C2 – Inclusion Criteria
BRAF mutation
Thyroid Gland Papillary Carcinoma
PLX8394 + cobicistat
Sensitive: C3 – Early Trials
BRAF V600
Thyroid Gland Papillary Carcinoma
BGB-283
Sensitive: C3 – Early Trials
BRAF mutation
Thyroid Gland Papillary Carcinoma
dabrafenib
Sensitive: C3 – Early Trials
RET fusion
Thyroid Gland Papillary Carcinoma
cabozantinib tablet
Sensitive: C3 – Early Trials
BRAF V600E
Thyroid Gland Papillary Carcinoma
siltuximab
Sensitive: C4 – Case Studies
PDGFRB overexpression
Thyroid Gland Papillary Carcinoma
larotrectinib
Sensitive: C4 – Case Studies
EGFR overexpression
Thyroid Gland Papillary Carcinoma
larotrectinib
Sensitive: C4 – Case Studies
BRAF V600
Thyroid Gland Papillary Carcinoma
dabrafenib + SNR1611
Sensitive: C4 – Case Studies
NCOA4-RET fusion
Thyroid Gland Papillary Carcinoma
lenvatinib
Sensitive: C4 – Case Studies
TPM3-NTRK1 fusion
Thyroid Gland Papillary Carcinoma
AB106
Sensitive: C4 – Case Studies
GLI3 overexpression
Thyroid Gland Papillary Carcinoma
larotrectinib
Sensitive: C4 – Case Studies
GLI2 overexpression
Thyroid Gland Papillary Carcinoma
larotrectinib
Sensitive: C4 – Case Studies
GLI1 overexpression
Thyroid Gland Papillary Carcinoma
larotrectinib
Sensitive: C4 – Case Studies
TPM3-NTRK1 fusion
Thyroid Gland Papillary Carcinoma
larotrectinib
Sensitive: C4 – Case Studies
NTRK1 overexpression
Thyroid Gland Papillary Carcinoma
larotrectinib
Sensitive: C4 – Case Studies
BRAF V600E + TERT mutation
Thyroid Gland Papillary Carcinoma
trametinib + dabrafenib
Resistant: C4 – Case Studies
BRAF V600E + TERT mutation
Thyroid Gland Papillary Carcinoma
sorafenib
Resistant: C4 – Case Studies
NRAS Q61K + BRAF V600E
Thyroid Gland Papillary Carcinoma
vemurafenib
Sensitive: C4 – Case Studies
PTEN R130del
Thyroid Gland Papillary Carcinoma
MK-2206
Sensitive: D – Preclinical
BRAF mutation
Thyroid Gland Papillary Carcinoma
PP2
Sensitive: D – Preclinical
RET-PTC1 rearrangement
Thyroid Gland Papillary Carcinoma
MK-2206
Sensitive: D – Preclinical
PIK3CA E545K
Thyroid Gland Papillary Carcinoma
MK-2206
Sensitive: D – Preclinical
RET rearrangement
Thyroid Gland Papillary Carcinoma
MK-2206
Sensitive: D – Preclinical
RET-PTC1 rearrangement
Thyroid Gland Papillary Carcinoma
dasatinib + CI-1040
Sensitive: D – Preclinical
RET-PTC1 rearrangement
Thyroid Gland Papillary Carcinoma
dasatinib
Sensitive: D – Preclinical
RET-PTC1 rearrangement
Thyroid Gland Papillary Carcinoma
cabozantinib capsule
Sensitive: D – Preclinical
RET-PTC1 rearrangement
Thyroid Gland Papillary Carcinoma
CI-1040 + SU6656
Sensitive: D – Preclinical
RET-PTC1 rearrangement
Thyroid Gland Papillary Carcinoma
CI-1040 + PP2
Sensitive: D – Preclinical
RET-PTC1 rearrangement
Thyroid Gland Papillary Carcinoma
CI-1040
Sensitive: D – Preclinical
RET-PTC1 rearrangement
Thyroid Gland Papillary Carcinoma
AZD1480
Sensitive: D – Preclinical
RET C634W
Thyroid Gland Papillary Carcinoma
AZD1480
Sensitive: D – Preclinical
RET M918T
Thyroid Gland Papillary Carcinoma
AZD1480
Sensitive: D – Preclinical
BRAF V600E
Thyroid Gland Papillary Carcinoma
trametinib + dabrafenib + AZD1775
Sensitive: D – Preclinical